Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 50%Moderate 1 · 50%High 0 · 0%

Serum uric acid <6.0 mg/dL at final visit · patients with chronic cout

Febuxostat 120 mg/day may leads to higher serum uric acid <6.0 mg/dL at final visit compared with placebo (low certainty).

1 finding from 1 review

Febuxostat for treating chronic gout 2012 · Cochrane Headline outcomes only
RR 80.7 [16, 405.5]
2 studies · 356 participants
Low

Serum uric acid <6.0 mg/dL at final visit · people with chronic gout

Febuxostat 120 mg/day probably leads to higher serum uric acid <6.0 mg/dL at final visit compared with allopurinol (moderate certainty).

1 finding from 1 review

Febuxostat for treating chronic gout 2012 · Cochrane Headline outcomes only
RR 2.2 [1.9, 2.5]
2 studies · 880 participants
Moderate